MAPK7 and plasma cell myeloma: In fact, this promising antitumor agent is currently undergoing phase I trials in leukemia and multiple myeloma patients, providing the first clues to the benefits of targeting the MEK5/ERK5 cascade in clinical practice, and encouraging other ERK5-specific inhibitors such as XMD8-92 to progress into clinical evaluation.